NCT05501821

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

A Phase I, First-in-human, Multicenter, Open-label, Dose Escalation Followed by an Expansion Phase Clinical Study of KBA1412 Given as Monotherapy or in Combination With Pembrolizumab in Adults With Advanced Solid Malignant Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Kling Biotherapeutics B.V. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to assess the safety and efficacy of KBA1412, a patient derived, fully human, monoclonal antibody targeting CD9, in patients with advanced solid malignant tumors

Detailed description

Patient interested in participation in a clinical study will be informed about the study and potential risks, all patients giving written informed consent will undergo a 3-week screening period to determine their eligibility for entry in the study. Patients will receive KBA1412 or KBA1412 in combination with pembrolizumab.

Conditions

• Advanced Solid Tumor Malignancy

Interventions

Type	Name	Description
DRUG	KBA1412	Part A, B, C
DRUG	Pembrolizumab	Part C only

Timeline

• Start date: 2022-08-08
• Primary completion: 2024-07-24
• Completion: 2024-07-24
• First posted: 2022-08-15
• Last updated: 2025-09-25

Locations

5 sites across 2 countries: Belgium, Netherlands